INTRODUCTION Antifibrinolytic agents are commonly used during cardiac surgery to minimize bleeding. Because of safety concerns, aprotinin was withdrawn from the market in 2007. Since then, tranexamic acid (TXA) has become the antifibrinolytic treatment of choice in many heart centers. The safety profile of TXA has not been extensively studied. Therefore, the aim of this study was to evaluate sa...

BACKGROUND This meta-analysis aimed to illustrate the efficacy and safety of combined topical and intravenous (IV) tranexamic acid (TXA) for blood loss control in primary total knee arthroplasty (TKA) patients. METHODS In April 2017, a systematic computer-based search was conducted in PubMed, EMBASE, Web of Science, Cochrane Database of Systematic Reviews, and Google database. Data on patient...

Post-partum haemorrhage (PPH) contributes to approximately 25% of maternal death globally. Tranexamic acid (TXA) has been confirmed be effective in reducing post-partum blood loss, thereby preventing PPH and its possible sequelae. This clinical controlled trial compared the efficacy a single dose 0.5g intravenous TXA 1g prevention primary among high-risk parturient women teaching hospital. A to...

Purpose Tranexamic acid (TXA) is effective in reducing blood loss in primary total knee replacement. Almost all studies used an intravenous form or a topical form. The aim of this study was to assess the blood sparing efficacy and the safety of oral TXA. Materials and Methods All patients with primary total knee replacement performed in our institute from January 2015 to October 2015 were eli...

PURPOSE Use of tranexamic acid (TXA) in the setting of arthroplasty of the lower extremity has been previously described. The aim of this study was to evaluate the benefit of a single dose of TXA (500 mg vial) administered intravenously just prior to RTSA in an Asian population. METHODS The records of 48 patients (no TXA, n = 24, versus TXA, n = 24) that underwent RTSA for cuff tear arthropat...

OBJECTIVES To test whether administration of the antifibrinolytic drug tranexamic acid (TXA) in patients with spontaneous intracerebral haemorrhage (SICH) leads to increased prevalence of diffusion-weighted MRI-defined hyperintense ischaemic lesions (primary hypothesis) or reduced perihaematomal oedema volume, perihaematomal diffusion restriction and residual MRI-defined SICH-related tissue dam...

Tranexamic acid (TXA) has anti-plasmin activity and been shown when administered orally to be effective against melasma, for which it is considered first-line pharmacotherapy. Several studies have that topically applied TXA also melasma skin hyperpigmentation caused by sunburn inflammation. The concentration in the epidermis dermis/vasculature estimated from its distribution after closed applic...

OBJECTIVE To characterize the relationship between tranexamic acid (TXA) use and patient outcomes in a severely injured civilian cohort, and to determine any differential effect between patients who presented with and without shock. BACKGROUND TXA has demonstrated survival benefits in trauma patients in an international randomized control trial and the military setting. The uptake of TXA into...

Objective To perform an economic evaluation of tranexamic acid (TXA) versus no-TXA, in addition to current clinical practice, for acute gastrointestinal bleeding, using the results HALT-IT trial ( NCT01658124 ), a large randomised controlled which included 11 937 patients. Design A cost-effectiveness modelling analysis, performed over lifetime time horizon. Setting The analysis was from UK heal...

Background: Blood loss during and immediately after total knee arthroplasty (TKA) is among the most challenging concerns. It has been demonstrated that Tranexamic acid (TXA) can help to reduce perioperative blood loss. TXA can be used as an oral, topical or intravenous injection. Many studies evaluated the effectiveness of each route of administration but few works on a comparison between them....